Standout Papers
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (2018)
- Dose escalation of a curcuminoid formulation (2006)
- ICOS Receptor Instructs T Follicular Helper Cell versus Effector Cell Differentiation via Induction of the Transcriptional Repressor Bcl6 (2011)
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression (2018)
Citation Impact
11 by Nobel laureates 13 from Science/Nature 76 standout
Citing Papers
Renal Cell Carcinoma
2024 Standout
Immune-related adverse events and the balancing act of immunotherapy
2022 Standout
Works of Christopher D. Lao being referenced
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
2018 Standout
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
2017
Author Peers
| Author | Oncology | Molecular Biology | Immunology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|
| Christopher D. Lao | 4415 | 2214 | 3064 | 119 | 8.1k | |
| P. S. REDDY | 3 | 39 | 59 | 14 | 445 | |
| Ernst D. Dickmanns | 3 | 45 | 1.1k | |||
| K Kaida | 96 | 9 | 138 | 12 | 357 | |
| Richard Gayle | 5 | 1 | 15 | 298 | ||
| Swati S. Nigudkar | 436 | 4 | 8 | 540 |
All Works
Loading papers...